Digital biomarkers can change dementia tracking: IISc professor

Prof KVS Hari, director of the Centre for Brain Research at IISc Bengaluru, emphasized digital biomarkers for early detection and prevention of dementia. He noted that India's rapidly aging population makes dementia a major public health challenge. The centre focuses on data collection and AI to understand disease progression in the Indian context.

Prof KVS Hari, director of the Centre for Brain Research (CBR) at IISc Bengaluru, discussed dementia research in an interview with the Indian Express. Funded initially by a gift from the Pratiksha Trust of Infosys co-founder Kris Gopalakrishnan, CBR studies the aging brain and related disorders. Hari stated, 'By 2030, India will have around 340 million elderly, with roughly 7.4% affected by dementia.' In India, dementia is often dismissed as normal aging, receiving limited policy attention.

Dementia, encompassing Alzheimer's, Parkinson's, and vascular types, progresses 15-20 years before clinical diagnosis. Hari noted that despite decades of animal model research, no cure exists for Alzheimer's; the 2024-approved drug only delays onset by six to eight months. Thus, CBR focuses on human-derived early biomarkers using multimodal data, emphasizing lifestyle interventions like exercise, diet, and sleep.

Western drugs may not fully apply due to Indian genetics. In India, diabetes and hypertension onset a decade earlier, accelerating dementia. CBR launched an urban cohort in 2015 with 1,000 Bengaluru residents, involving annual assessments: clinical evaluations, blood samples, cognitive tests, MRI, OCT, audiometry, gait analysis, and more. A rural cohort in Kolar district started in 2018, targeting 10,000 participants with biennial follow-ups; first-round enrollment completed in February 2025.

Challenges include participant retention in longitudinal studies and building diverse datasets. Opportunities lie in non-pharmacological interventions, personalized lifestyle protocols, and digital tools like apps monitoring speech and gait. Blood-based plasma protein biomarkers and wearables enable continuous screening. Hari said, 'AI can detect patterns in multi-modal data that other methods miss.' Startups are developing speech-based diagnostics and portable low-field MRI. CBR is pushing for national cognitive data repositories to address fragmented health data.

Liittyvät artikkelit

Realistic split-image illustration showing obesity-linked faster rise in Alzheimer’s blood biomarkers versus normal weight, highlighting blood tests detecting changes earlier than brain scans.
AI:n luoma kuva

Obesity linked to faster rise in Alzheimer’s blood biomarkers, study finds

Raportoinut AI AI:n luoma kuva Faktatarkistettu

New research finds that blood biomarkers associated with Alzheimer’s disease increase significantly faster in people with obesity than in those without. Drawing on five years of data from 407 volunteers, the study suggests that blood tests can detect obesity‑related changes earlier than brain scans, underscoring obesity as a major modifiable risk factor for Alzheimer’s.

Scientists at Brown University have identified a subtle brain activity pattern that can forecast Alzheimer's disease in people with mild cognitive impairment up to two and a half years in advance. Using magnetoencephalography and a custom analysis tool, the researchers detected changes in neuronal electrical signals linked to memory processing. This noninvasive approach offers a potential new biomarker for early detection.

Raportoinut AI Faktatarkistettu

A large study published in Neurology finds that impaired kidney function is linked to higher levels of Alzheimer’s biomarkers in the blood, without increasing overall dementia risk. However, among people who already have elevated biomarker levels, poor kidney health may hasten when dementia symptoms appear, underscoring the need to factor kidney function into interpretation of Alzheimer’s blood tests.

A large study of nearly 2 million older adults has found that cerebral amyloid angiopathy, a condition where amyloid proteins build up in brain blood vessels, sharply increases the risk of dementia. Within five years of diagnosis, people with this disorder were four times more likely to develop dementia than those without it, even absent a history of stroke. The findings, drawn from Medicare records, underscore the need for early cognitive screening in affected individuals.

Raportoinut AI Faktatarkistettu

Scientists at Northern Arizona University are developing a non-invasive blood test that could help detect Alzheimer’s disease before symptoms appear by examining how the brain uses glucose through tiny blood-borne microvesicles. Led by assistant professor Travis Gibbons and supported in part by the Arizona Alzheimer’s Association, the project aims to enable earlier diagnosis and intervention, similar to how doctors manage cardiovascular disease.

A 20-year randomized controlled trial has shown that cognitive speed training, combined with booster sessions, reduces the risk of dementia diagnosis by 25 percent among older adults. The study, involving over 2,800 participants aged 65 and older, focused on a computer-based task requiring quick recall of visual details. While results are promising, experts urge caution due to the study's multiple outcome measures.

Raportoinut AI

A large-scale international study has found that age-related memory decline stems from broad structural changes across the brain, rather than a single region or gene. Analyzing over 10,000 MRI scans from thousands of healthy adults, researchers observed that brain shrinkage's impact on memory intensifies nonlinearly in later life. The findings highlight a distributed vulnerability that accelerates memory loss once a tipping point is reached.

 

 

 

Tämä verkkosivusto käyttää evästeitä

Käytämme evästeitä analyysiä varten parantaaksemme sivustoamme. Lue tietosuojakäytäntömme tietosuojakäytäntö lisätietoja varten.
Hylkää